| ￥3300 | |
| Z05953-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||||
| Endotoxin Level | Less than 1 EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized VEGF165, His & Avi, Human at 0.5 μg/ml (100 μl/well) on the plate can bind Anti?VEGF165 Antibody, hFc Tag. Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 22.2 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 28-35 kDa under reduced (R) condition, 45-60 kDa under Non reducing (N) condition based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. |
| Synonyms | VEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609;VEGF-165 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
